ALX Oncology GAAP EPS of -$0.49 misses by $0.04

* ALX Oncology press release [https://seekingalpha.com/pr/20198601-alx-oncology-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:ALXO [https://seekingalpha.com/symbol/ALXO]): Q2 GAAP EPS of -$0.49 misses by $0.04.
* Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2025, were $83.5 million. The Company believes its cash, cash equivalents and investments are sufficient to fund planned operations into Q1 of 2027.
*  

MORE ON ALX ONCOLOGY

* Seeking Alpha’s Quant Rating on ALX Oncology [https://seekingalpha.com/symbol/ALXO/ratings/quant-ratings]
* Historical earnings data for ALX Oncology [https://seekingalpha.com/symbol/ALXO/earnings]
* Financial information for ALX Oncology [https://seekingalpha.com/symbol/ALXO/income-statement]